The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRRγ, which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.
本发明涉及新型
维生素 D 受体相关(VDRR)
多肽以及含有这些
多肽的制剂。本发明还公开了编码 VDRR
多肽的核酸序列、含有此类序列的表达载体和用此类表达载体转化的宿主细胞,以及表达本发明新型 VDRR
多肽的方法。本发明进一步涉及用作药物的 VDRR
多肽,以及使用影响 VDRR
信号转导的物质制造治疗代谢、增殖或炎症疾病的药物。本发明还涉及鉴定编码 VDRR
多肽的克隆的方法、鉴定 VDRR
配体的方法和鉴定用于治疗受 VDRR
多肽影响的病症的物质的方法。更具体地说,新型 VDRR
多肽可以是被指定为 VDRRγ 的
多肽,它可以被任何与已知核受体
配体结构相似的小
化学分子调节。